Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$22.80 USD

22.80
180,556

+0.15 (0.66%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?

LivaNova (LIVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 5th

AVNS, NKE and PLAB have been added to the Zacks Rank #5 (Strong Sell) List on October 5, 2022.

New Strong Sell Stocks for September 28th

AVNS, ARCE and DCO have been added to the Zacks Rank #5 (Strong Sell) List on September 28, 2022.

Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?

Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered

Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.

Avanos Medical (AVNS) Surpasses Q2 Earnings Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.13% and 2.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Integer (ITGR) Q2 Earnings Miss Estimates

Integer (ITGR) delivered earnings and revenue surprises of -11.86% and 1.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?

Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What to Expect From Molina Healthcare's (MOH) Q2 Earnings?

Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.

Can Avanos Medical (AVNS) Keep the Earnings Surprise Streak Alive?

Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Tandem Diabetes Care, Inc. (TNDM) Soars 6%: Is Further Upside Left in the Stock?

Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates

Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.

Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.

HCA Healthcare (HCA) Q1 Earnings Miss, Trims '22 EPS View

HCA Healthcare's (HCA) first-quarter results reflect elevated expenses related to salaries and benefits, partly offset by an uptick in revenues driven by higher patient admissions.

Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?

Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.

Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?

Ecolab's (ECL) first-quarter results are likely to reflect continued strength across its business segments.

Anthem (ANTM) Q1 Earnings Beat Estimates, Hikes '22 EPS View

Anthem's (ANTM) first-quarter results indicate solid top-line growth and strong contribution from each of its businesses, partly offset by higher expenses.